Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph T Barbieri

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
The Journal of Biological Chemistry|January 14, 2014
The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motifNathan J Schuld, Jeffrey S Vervacke, Ellen L Lorimer, et al.
Infection and Immunity|September 24, 2005
Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and EMichael R Baldwin, William H Tepp, Christina L Pier, et al.
The Journal of Infectious Diseases|January 25, 2002
Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosaBruce Banwart, Mark L Splaingard, Philip M Farrell, et al.
ACS Medicinal Chemistry Letters|October 21, 2010
Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain ProteaseLisa M Eubanks, Peter Silhár, Nicholas T Salzameda, et al.
ACS Medicinal Chemistry Letters|April 9, 2013
The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic CleftPeter Silhár, Matthew A Lardy, Mark S Hixon, et al.
Organic Letters|January 23, 2010
Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a proteaseG Neil Stowe, Peter Silhár, Mark S Hixon, et al.
Vaccine|July 25, 2022
Genetically detoxified tetanus toxin as a vaccine and conjugate carrier proteinMin-Ju Chang, Morgane Ollivault-Shiflett, Richard Schuman, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 5, 2012
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trialMichael Anstead, Sonya L Heltshe, Umer Khan, et al.
Vaccines|December 23, 2023
Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate VaccinesDavide Oldrini, Roberta Di Benedetto, Martina Carducci, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 13, 2011
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitorJing Zhao, Yuhong Du, John R Horton, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
The Journal of Biological Chemistry|January 14, 2014
The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motifNathan J Schuld, Jeffrey S Vervacke, Ellen L Lorimer, et al.
Infection and Immunity|September 24, 2005
Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and EMichael R Baldwin, William H Tepp, Christina L Pier, et al.
The Journal of Infectious Diseases|January 25, 2002
Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosaBruce Banwart, Mark L Splaingard, Philip M Farrell, et al.
ACS Medicinal Chemistry Letters|October 21, 2010
Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain ProteaseLisa M Eubanks, Peter Silhár, Nicholas T Salzameda, et al.
ACS Medicinal Chemistry Letters|April 9, 2013
The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic CleftPeter Silhár, Matthew A Lardy, Mark S Hixon, et al.
Organic Letters|January 23, 2010
Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a proteaseG Neil Stowe, Peter Silhár, Mark S Hixon, et al.
Vaccine|July 25, 2022
Genetically detoxified tetanus toxin as a vaccine and conjugate carrier proteinMin-Ju Chang, Morgane Ollivault-Shiflett, Richard Schuman, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 5, 2012
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trialMichael Anstead, Sonya L Heltshe, Umer Khan, et al.
Vaccines|December 23, 2023
Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate VaccinesDavide Oldrini, Roberta Di Benedetto, Martina Carducci, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 13, 2011
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitorJing Zhao, Yuhong Du, John R Horton, et al.
Pageof 11